Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 5/20 | 0.66 |
| ▸ | NOS3 | P29474 | 3/20 | 0.66 |
| ▸ | NOS1 | P29475 | 3/20 | 0.66 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 2/20 | 0.49 |
| ▸ | GABRD | O14764 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.49 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.49 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.49 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.49 |
| ▸ | GABRE | P78334 | 2/20 | 0.49 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.49 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.49 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.49 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL729575 | 0.94 | NOS3 (0.63) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL5749578 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL8527159 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL11553700 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL3443609 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL5746040 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL27678823 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL19309208 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL5744814 | 0.93 | NOS3 (0.61) | NOS2NOS3NOS1SKP2GABRP | |
| SCHEMBL105611 | 0.88 | NOS2 (0.70) | NOS2NOS3NOS1GABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION | 2024-01-25 | — | — | US | disclosed |
| EP-4232449-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | Celgene Corporation (US) | 2023-08-30 | — | — | EP | disclosed |
| CN-116547282-A | Heterocyclic compounds and their use for the treatment of helminth infections and diseases | 新基公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2022087326-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CELGENE CORPORATION (US) | 2022-04-28 | — | — | WO | disclosed |
| CN-101171014-B | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-02-15 | — | — | CN | disclosed |
| CN-101171014-A | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARM LTD (IE) | 2008-04-30 | — | — | CN | disclosed |
| US-20070105832-A1 | Substituted azetidinones | Cadrenal Therapeutics, Inc. | 2007-05-10 | — | — | US | disclosed |
| CN-1438991-A | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER CIMITED (US) | 2003-08-27 | — | — | CN | disclosed |
| EP-1296938-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | Pfizer Limited (GB) | 2003-04-02 | — | — | EP | disclosed |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | PFIZER, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002002513-A1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE DERIVATIVES AS INHIBITORS OF NEUTRAL ENDOPEPTIDASE | PFIZER LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
| US-4115397-A | 1,3,5,7-TETRA(2-PYRIDYLIMINO)-BENZODIPYRROLES | FORD MOTOR COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105832-A1 | Substituted azetidinones | F2R, CPA3, CFD | NOS2 4131/4885NOS3 3183/4885NOS1 3992/4885 |
| US-20240025891-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | CYP8B1, PAH, INHA | NOS2 2054/4885NOS3 2481/4885NOS1 3329/4885 |
| US-20020052370-A1 | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase | ENGASE, ENPEP, CPN1 | NOS2 2122/4885NOS3 1510/4885NOS1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.